Genetic testing for prostate cancer is rapidly growing and is increasingly being driven by precision medicine. Rates of germline pathogenic variants have been reported in up to 15% of men with prostate cancer, particularly in metastatic disease, and results of genetic testing could uncover options for precision therapy along with a spectrum of hereditary cancer-predisposition syndromes with unique clinical features that have complex management options. Thus, the pre-test discussion, whether delivered by genetic counsellors or by health-care professionals in hybrid models, involves information on hereditary cancer risk, extent of gene testing, purpose of testing, medical history and family history, potential types of results, additional cancer risks that might be uncovered, genetically based management and effect on families. Understanding precision medicine, personalized cancer risk management and syndrome-related cancer risk management is important in order to develop collaborative strategies with genetic counselling for optimal care of patients and their families.

前列腺癌的基因检测正在迅速发展，并且越来越多地受到精准医学的推动。据报道，高达 15% 的前列腺癌患者存在种系致病变异率，尤其是在转移性疾病中，基因检测的结果可以揭示精准治疗的选择以及一系列具有独特临床特征的遗传性癌症易感综合征有复杂的管理选项。因此，无论是由遗传咨询师还是混合模型中的医疗保健专业人员提供的检测前讨论，都涉及有关遗传性癌症风险、基因检测范围、检测目的、病史和家族史、潜在结果类型的信息，可能被发现的其他癌症风险、基于基因的管理和对家庭的影响。